acute myocardial infarction

The MGuard stent shows a trend toward reduced mortality in PCI

Original title:&nbsp;Mesh-Covered Embolic Protection Stent Implantation in ST-Segment&ndash;Elevation Myocardial Infarction. Final 1-Year Clinical and Angiographic Results From the MGUARD for Acute ST Elevation Reperfusion Trial.&nbsp;Reference:&nbsp;DariuszDudek et al. CircCardiovascInterv. 2015 Feb;8(2). &nbsp; The MGuard is a micronet mesh-covered stent designed to reduce distal embolization in the context of ST elevation myocardial infarction. In the MASTER study<a href="https://solaci.org/en/2015/02/23/the-mguard-stent-shows-a-trend-toward-reduced-mortality-in-pci/" title="Read more" >...</a>

Net clinical benefit of bivalirudin in STEMI patients

Original title:&nbsp;Bivalirudin Versus Heparin With or Without Glycoprotein IIb/IIIa Inhibitors in Patients With STEMI Undergoing Primary Percutaneous Coronary Intervention: Pooled Patient-Level Analysis From the HORIZONS-AMI and EUROMAX Trials.&nbsp;Reference:&nbsp;Stone GW et al. J Am CollCardiol. 2015 Jan 6;65(1):27-38. The HORIZONS-AMI (Harmonizing Outcomes with RevasculariZatiON and Stents in Acute Myocardial Infarction) that included 3602 STEMI patients undergoing<a href="https://solaci.org/en/2015/01/29/net-clinical-benefit-of-bivalirudin-in-stemi-patients/" title="Read more" >...</a>

Never ending controversy over the duration of post DES dual antiplatelet therapy

Original title:&nbsp;Second Generation Drug-Eluting Stents Implantation Followed by Six Versus Twelve-Month &#8211; Dual Antiplatelet Therapy- The SECURITY Randomized Clinical Trial.&nbsp;Reference:&nbsp;Antonio Colombo et al. J Am CollCardiol. 2014 Nov 18;64(20):2086-97. The optimal duration of dual antiplatelet therapy after second-generation DES implantation is still debated and apparently will remain controversial for some time. The aim of this<a href="https://solaci.org/en/2015/01/15/never-ending-controversy-over-the-duration-of-post-des-dual-antiplatelet-therapy/" title="Read more" >...</a>

Lower Rates of In-Stent Thrombosis with the New Generation DES

Original title:&nbsp;New-generation drug-eluting stents reduce stent thrombosis and myocardial infarction: a propensity-score-adjusted analysis from the multicenter REAL registry.&nbsp;Reference:&nbsp;Vignali L et al. Cath Cardiovasc Interv. 2014; Epub ahead of print. Compared to the first generation of drug eluting stents (DES), the new generation has a lower long term risk of in-stent thrombosis and acute myocardial infarction<a href="https://solaci.org/en/2014/10/30/lower-rates-of-in-stent-thrombosis-with-the-new-generation-des/" title="Read more" >...</a>

Increased security with bivalirudin than with heparin alone in patients without ST segment.

Original title:&nbsp;Heparin monotherapy or bivalirudin during percutaneous coronary intervention in patients with non-ST-segment elevation acute coronary syndromes or stable ischemic heart disease: results from the Evaluation of Drug-Eluting Stents and Ischemic Events registry.&nbsp;Reference:&nbsp;Bangalore S et al. CircCardiovascInterv. 2014;Epub ahead of print. Bivalirudin compared to unfractionated heparin as monotherapy is associated with a lower risk of<a href="https://solaci.org/en/2014/05/14/increased-security-with-bivalirudin-than-with-heparin-alone-in-patients-without-st-segment/" title="Read more" >...</a>

Blush reduction in a not responsible vessel is a prognostic marker in those receiving angioplasty in the culprit vessel.

Original title:&nbsp;Impact of Nonculprit Vessel Myocardial Perfusion on Outcomes of Patients Undergoing Percutaneos Coronary OIntervention for Acute Coronary S&iacute;ndromes. Analysis From ACUITY Trial.&nbsp;Reference:&nbsp;Alexandra Lansky, et al. JAAC Cardiovascular Intervention 2014,7:266-275 In Non ST elevation Acute Coronary Syndrome (NSTE-ACS) is demonstrated that revascularization of the culprit vessel is beneficial, but strategy it is not yet clear<a href="https://solaci.org/en/2014/05/09/blush-reduction-in-a-not-responsible-vessel-is-a-prognostic-marker-in-those-receiving-angioplasty-in-the-culprit-vessel/" title="Read more" >...</a>

Higher event rate in those with non-ST elevation ACS who received revascularization at PLATO study. Beyond this, ticagrelor reduced mortality.

Original title:&nbsp;Ticagrelor vs. clopidogrel in patients with non-ST-elevation acute coronary syndrome with or without revascularization: results from the PLATO trial.&nbsp;Reference:&nbsp;Lindholm D et al. Eur Heart J. 2014; Epub ahead of print. The PLATO study randomized 18624 patients with ACS to aspirin and ticagrelor (180 mg loading dose followed by 90 mg every 12 hours) versus<a href="https://solaci.org/en/2014/05/07/higher-event-rate-in-those-with-non-st-elevation-acs-who-received-revascularization-at-plato-study-beyond-this-ticagrelor-reduced-mortality/" title="Read more" >...</a>

Deferred Stenting in Primary Angioplasty could reduce No Reflow Risk and Infarct Size.

Original:&nbsp;A Randomized Trial of Deferred Stenting versus Immediate Stenting to Prevent No-or Slow Reflow in Acute ST-Elevation Myocardial Infarction (DEFER-STEMI).&nbsp;Reference:&nbsp;David Carrick et al. J Am Coll Cardiol. 2014. Epub ahead of print. No Reflow physiopathology involves microvascular obstruction secondary to thrombus embolization, spasm or microvascular thrombosis, and happens in approximately 10% of PCI procedures. The<a href="https://solaci.org/en/2014/03/17/deferred-stenting-in-primary-angioplasty-could-reduce-no-reflow-risk-and-infarct-size/" title="Read more" >...</a>

Best results of angioplasty with DES guided by IVUS versus angiography only

Original title:&nbsp;Intravascular Ultrasound-Guided Implantation of Drug-Eluting Stents to Improve Outcome. A Meta-Analysis.&nbsp;Reference:&nbsp;Jae-Sik Jang et al. J Am Coll Cardiol Intv 2014, epub ahead of print. Several previous studies and meta-analysis showed that implantation of conventional stents (BMS) intravascular ultrasound (IVUS) guided may decrease restenosis and clinical events. This information was not yet clear to drug-eluting<a href="https://solaci.org/en/2014/02/26/best-results-of-angioplasty-with-des-guided-by-ivus-versus-angiography-only/" title="Read more" >...</a>

3rd generation zotarolimus-eluting stent non- inferior to everolimus

Original title:&nbsp;Third-generation zotarolimus-eluting and everolimus-eluting stents in all-comer patients requiring a percutaneous coronary intervention (DUTCH PEERS): a randomized, single-blind, multicentre, non-inferiority trial.&nbsp;Reference:&nbsp;Von Birgelen C et al. The Lancet. 2014; Epub ahead of print. In the 3rd generation zotarolimus-eluting stent, platform was modified to increase flexibility and make implant easier in complex lesions. This study was<a href="https://solaci.org/en/2014/02/13/3rd-generation-zotarolimus-eluting-stent-non-inferior-to-everolimus/" title="Read more" >...</a>

Top